The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Higher Adalimumab Trough Level Not Linked to Increased Adverse Events in IBD Treatment
Data show adverse events occurred in 6.67% in the cohort of patients with IBD.
Vedolizumab Safe and Effective Treating Inflammatory Bowel Disease
Most of the data on vedolizumab has been limited by small sample sizes and short follow-up.
Charles Owen, MD: An Overview on Cologuard at DDW
About a quarter of Cologuard's ordered by patients are deemed to be inappropriate.
Florian Rieder, MD: Ozanimod as a Treatment for Ulcerative Colitis
Infections in patients with ulcerative colitis treated with ozanimod were mostly characterized as non-serious.
RBX2660 Shows Promise as a C Difficile Treatment
The treatment would represent the first microbiota-based live biotherapeutic to show efficacy in the first recurrence of CDI.
Acute Pancreatitis Linked to Adverse Outcomes in Patients with Bone Marrow Transplantation
Data show adverse outcomes include increased mortality rates, prolonged hospital stay, and higher hospitalization chargers.
Non-Alcoholic Fatty Liver Disease Associated with Increased Global Burden
Data show global burden of NAFLD increased, while burden of cirrhosis decreased in adolescents and young adults.
Fatigue Linked to Higher Levels of IBD Disease
Ulcerative colitis patients with fatigue are more likely to be unemployed, have moderate or severe disease, and higher Mayo scores.
Significant Correlation Found Between Male Patients with HCV, Advanced Fibrosis
Data show males, patients with high BMI correlated with higher FAST score in HCV care.
Long-Term Ustekinumab Treatment Associated With Improved Quality of Life
Data show clinically meaningful improvement in IBDQ score and MCS score in patients treated with UST.
New Initiatives Improve Vaccination Rates in Pediatric Patients with IBD
Data show a 23.5% increase in influenza vaccination rates.
Opioid Treatment, Low BMI Linked to Severe Infection in Patients with IBD
Data show biologic therapy was not associated with ICU admission or death due to infection.
Alpesh Amin, MD: The Challenge of Treating C Difficile Infections
C difficile and sepsis infections can be especially difficult to treat.
High Efficacy Marks for Investigational Treatment for C Difficile Infections
SER-109 resulted in a 73% reduction in relative risk for CDI over 8 weeks.
Similar Outcomes Identified in Comparison of C.Diff of Small Bowel and Colon
Hospitalizations were more likely in patients with CDI of small bowel and Crohn's disease, with worse outcomes noted in patients admitted to ICU.
Christie Teigland, PhD: The Cost of C Difficile and Sepsis
There is a substantial health care cost for CDI patients with sepsis.
C Diff Rates Decreasing Due to Enhanced COVID-19 Measures
In data presented at DDW, researchers find a decrease in hospital-acquired CDI infections in 2020 when compared to 2018 and 2019.
Primary Prevention of Arrythmias Lags Behind Secondary Prevention
More and more individuals are becoming diagnosed with atrial fibrillation. But the research to halt this crisis is not quite there yet.
Fighting and Reducing Stressors in Cardiology
A survey at ACC 2021 showed 38% of cardiology professionals were burnt out during COVID-19. What factors in the field have already made it difficult to cope?
Why Peripheral Arterial Disease Lacks Clinical Research
The high-risk patient population is under-represented in new research and agents. Why characteristics set it apart from other cardiovascular diseases?
Meta-Analysis Highlights Acute Coronary Syndrome Risk Window
New data suggest 90 days following an initial ACS event is the greatest time of likelihood for another high-risk event. How can this inform cardiovascular research?
Rivaroxaban Improves Total Ischemic Events in New VOYAGER PAD Analysis
Marc Bonaca, MD, explains the value of new assessments made in the pivotal peripheral artery disease clinical trial.
Survey: COVID-19 Drove Burnout Among Cardiology Care Team Members
A cardiologist and wellness expert discusses new findings showing more than one-third of her peers were burnt out from experiences during the pandemic.
VOYAGER PAD with Manesh Patel, MD, and Schuyler Jones, MD
The Duke investigators return to discuss the pivotal study of rivaroxaban in peripheral artery disease.
Acute Alcohol Consumption May Trigger Discreet Atrial Fibrillation Event
There is no clear threshold for consumption leading to an AFib event.
Sotagliflozin Benefits Diabetic Patients with Various Types of Heart Failure
Patients with a preserved ejection fraction saw a significant reduction in risk for cardiovascular-related adverse events and mortality.
Evanicumab Benefits Genotypes of Severe Hypertriglyceridemia
New phase 2 data show the potential of the biologic in patients at risk of acute pancreatitis progression, but with a need for better variable understanding.
Reducing Cardiovascular Disease, Disparities in Women
Investigators discuss recently-published secondary sex-based assessments into PCI treatment, as well as their contribution to cardiovascular research action points that lessen the field's disparities.
Study Shows Atorvastatin Ineffective Against Severe COVID-19 Outcomes
Patients on atorvastatin experienced similar rates of adjudicated venous thromboembolism and all-cause mortality compared to placebo.
Restrictive Transfusions for Acute MI, Anemia Linked to Higher Risk for MACE
The 1-year follow-up of the REALITY trial presented at ACC undermines previously reported 30-day findings showing noninferiority to liberal transfusions.